Muller, Petr
Coates, Philip J.
Nenutil, Rudolf
Trcka, Filip
Hrstka, Roman
Chovanec, Josef
Brychtova, Veronika
Vojtesek, Borivoj
Funding for this research was provided by:
Horizon 2020 (ADOPT BBMRI-ERIC No. 676550)
Grantová Agentura České Republiky (GACR 16-07321S)
Ministerstvo Školství, Mládeže a Tělovýchovy (NPS I – LO1413, LM2015089)
Ministerstvo Zdravotnictví Ceské Republiky (DRO - MMCI 00209805)
Article History
Received: 11 January 2019
Accepted: 5 March 2019
First Online: 27 March 2019
Ethics approval and consent to participate
: Ethical approval for the use of anonymised excess tumour tissues for this research was granted by the Biobank of clinical samples at the Masaryk Memorial Cancer Institute, a member of the pan-European BBMRI (membership number AO192).
: RN, PM and BV are associated with Moravian Biotechnology, the company that produced and supplied the Tomm34 monoclonal antibody. The company did not provide financial support for the studies and had no influence on the design, execution or analysis of the experiments. The other authors have declared that no competing interests exist.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.